

23 April 2015

Resonance Health Ltd (ASX:RHT) Appendix 4C – 3rd Quarter Cash Flow Report

Resonance Health Limited today released its 3rd quarter Cash Flow Report for the period ending 31 March 2015.

Cash at 31 March 2015 was \$2.892million representing an increase of \$294k for the March quarter.

Receipts from customers for the March quarter were higher than the previous quarter as Resonance Health's prepaid Voucher programme continues to be appreciated by large pharma companies. The analytical services for the prepaid Voucher programme will be delivered over the coming 12 months.

The marketing spend in the March quarter, as planned, was \$55,000. Company delegates headed to China, France, Portugal and Singapore increasing awareness of HepaFat-Scan® and FerriScan® in the global clinical community.

In the coming quarter marketing activities will include attending the following events:


- the 2nd Liver Forum in Vienna focusing on HepaFat-Scan. The Liver Forum has key industry participants focused on drug development and diagnostics for the treatment of liver disease.
- the 50th International Liver Congress (European Association of the Study of the Liver) EASL in Vienna. Our most recent work on HepaFat-Scan will be presented.
- the Thalassaemia International Federation (TIF) conference in Athens. TIF is a significant body that advocates the use of FerriScan in thalassaemia patients.
- the "Digestive Disease Federation" London conference organised by the British Association of the Study of the Liver. Both FerriScan and HepaFat-Scan will be promoted to hepatology key opinion leaders. This conference combines four other societies including Gastroenterology and Gastrointestinal Surgery which are the key focus areas for Resonance Health.

Research and development spend was in line with our planned budget of \$66,000 focused on liver fibrosis test. Work on the fibrosis test continues to be a focus for the Company and multiple avenues are being explored.

The clinical community is expressing an interest in HepaFat-Scan and the Company is pursuing opportunities to participate in a number of studies both overseas and locally which are anticipated to start in the coming quarter. These studies will generate important data to enhance the acceptance and uptake of HepaFat-Scan and will support incorporation of HepaFat-Scan in clinical guidelines for the management of patients with fatty liver.

Resonance Health completed work on its new web site and new logo. The responsive design of the new web site allows easy access to portable devices such as tablets and mobile phones with improved speeds.

Investors can subscribe to our ASX market releases via our new web site. <http://www.resonancehealth.com/investors/asx-subscribe.html>



For further information please contact:

Resonance Health

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

31 March 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	976	1,907
1.2 Payments for		
(a) staff costs	(486)	(1,132)
(b) advertising and marketing	(55)	(254)
(c) research and development	(66)	(170)
(d) leased assets	-	-
(e) other working capital	(76)	(221)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	19	57
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	-	-
1.7 Other Receipts/Payments		
(a) consulting & professional services	(1)	(28)
(b) statutory & compliance	(17)	(124)
(c) grants	-	135
(d) Due diligence expense	-	(43)
Net operating cash flows	294	127

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitment

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)		
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	(4)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	-	(4)
1.14	Total operating and investing cash flows	294	123
Cash flows related to financing activities			
1.15	Proceeds from issues of shares, options, etc.	-	650
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	(19)
	Net financing cash flows	-	631
	Net increase (decrease) in cash held	294	754
1.21	Cash at beginning of quarter/year to date	2,584	2,097
1.22	Exchange rate adjustments to item 1.20	14	41
1.23	Cash at end of quarter	2,892	2,892

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	\$38k
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	\$38K – Directors fees	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	665	384
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details) - Term deposits	2,227	2,200
Total: cash at end of quarter (item 1.22)	2,892	2,584

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Adrian Bowers
Company Secretary